Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples